NCT03601702 EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke
| NCT ID | NCT03601702 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Niguarda Hospital |
| Condition | Acute Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-01-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.
Eligibility Criteria
Inclusion Criteria * Signed Informed Consent Form * Large Vessel Occlusion on CTA or MRA in the Anterior or Posterior Proximal Cerebral Vasculature up to A1, M1, Dominant M2, P1 * ASPECTS ≥ 6 * Mismatch or good collaterals showed at MR or multiphasic CTA or pCT * Groin Puncture performed within 12 hours from symptom onset * Use of EmboTrap® II Revascularization Device (Neuravi) as the first or second line treatment Exclusion criteria * Informed consent not given * Extracranial or tandem occlusion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03601702 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03601702 currently recruiting?
Yes, NCT03601702 is actively recruiting participants. Contact the research team at edoardo.bocccardi@ospedaleniguarda.it for enrollment information.
Where is the NCT03601702 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT03601702 clinical trial?
NCT03601702 is sponsored by Niguarda Hospital. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.